DEF 14A: Aptevo Seeks Shareholder Approval for $60M Equity Raise

Aptevo Therapeutics Inc. calls a special meeting to approve an amendment to its Certificate of Incorporation and a potential $60 million equity issuance under a Standby Equity Purchase Agreement.

Summary

• A special meeting of stockholders is scheduled for February 18, 2026, to be held virtually at 10 a.m. Pacific Time.
• Stockholders will vote on three proposals: approval of an Amended and Restated Certificate of Incorporation, approval of the potential issuance of 19.99% or more of common stock under a Standby Equity Purchase Agreement (SEPA) with Yorkville, and authorization to adjourn the meeting if necessary.
• The SEPA allows Aptevo to sell up to $60.0 million of common stock to Yorkville over 36 months, at a price equal to 96% of the lowest daily Volume Weighted Average Price (VWAP) during a three-day period, subject to a minimum acceptable price.
• As of January 15, 2026, the full $60.0 million in common stock remains available for issuance under the SEPA.
• The company paid Yorkville a $25,000 structuring fee and will pay a 2% commitment fee ($1.2 million) in five equal quarterly installments.
• The Board of Directors recommends voting 'FOR' all three proposals.
• As of January 9, 2026, there were 997,830 shares of common stock outstanding and entitled to vote.
• The SEPA Exchange Cap, which requires shareholder approval for issuances below a certain price, is 199,466 shares, representing 19.99% of outstanding common stock as of January 8, 2026.
• The Nasdaq closing price on January 8, 2026, was $9.20, and the 5-day average closing price preceding that date was $8.753 (the Minimum Price).
• As of January 15, 2026, the common stock price was $9.03 per share.

Sentiment

Score: 4

Explanation: The filing indicates a necessary capital raise through a potentially dilutive equity agreement, which is a common but often unfavorable method for existing shareholders. The history of multiple reverse stock splits further suggests ongoing financial challenges. While securing capital is positive, the terms and context point to underlying difficulties.

Positives

• The Standby Equity Purchase Agreement (SEPA) provides a reliable source of capital for working capital, capital expenditures, operating expenses, and business development opportunities.
• The company retains control over the timing and amount of any sales of shares to Yorkville under the SEPA, allowing for strategic deployment of capital.
• The SEPA offers flexibility in funding continued product research, development, or intellectual property acquisition.

Negatives

• The potential issuance of shares under the SEPA, if approved, will dilute existing stockholders' proportionate ownership, which may be material.
• Failure to approve the SEPA Share Issuance Proposal may impair working capital and the ability to fund operations and strategic initiatives, potentially forcing the company to seek less advantageous or more dilutive alternative financing.
• The company has undergone multiple reverse stock splits in recent years (2020, 2024, 2025, and December 2025), which often indicates a struggling stock price and can be a negative signal to investors regarding long-term value creation.

Risks

• Significant dilution of existing stockholders' proportionate ownership is a direct consequence of the potential issuance of common stock under the SEPA.
• If the SEPA Share Issuance Proposal is not approved, the company's working capital and ability to fund capital expenditures, operating expenses, and business development opportunities may be impaired.
• Non-approval of the SEPA Share Issuance Proposal could compel the company to explore alternative financing options that are less advantageous and potentially more dilutive.
• The Series A Preferred Stock has significant preferential rights, including high voting power (1,000 votes per share), preferential dividends, and liquidation preferences, which could negatively impact common stockholders' economic interests and influence.
• Holders of Series A Preferred Stock gain the right to elect two directors if dividends are six quarters in arrears, potentially impacting corporate control and board composition.
• High voting thresholds (75%) for certain corporate governance changes (bylaws, and Articles Sixth, Ninth, Tenth, Eleventh of the Certificate of Incorporation) could make future changes difficult without broad consensus, potentially entrenching current management or board decisions.

Future Outlook

The company anticipates that the Standby Equity Purchase Agreement (SEPA), if approved by stockholders, will provide a reliable source of capital for general corporate purposes, including working capital, capital expenditures, operating expenses, and the pursuit of business development opportunities, such as product research, development, or intellectual property acquisition. Management believes this flexibility is in the best interests of the company and its stockholders.

Management Comments

• The Board has determined that entering into the SEPA is in the best interests of us and our stockholders because the flexibility to issue shares of our common stock in excess of the SEPA Exchange Cap provides us with a reliable source of capital for working capital and general corporate purposes.
• We cannot predict the price of the common stock at any future date, and therefore cannot predict the number of shares of common stock to be issued under the SEPA or whether the applicable price for any such shares will be greater than the Minimum Price under the applicable Nasdaq rules.

Industry Context

The filing does not provide specific industry context or comparisons to competitors. However, the need for a Standby Equity Purchase Agreement (SEPA) and the history of multiple reverse stock splits suggest that Aptevo Therapeutics Inc. is likely a smaller biotechnology or pharmaceutical company facing ongoing capital needs for R&D and operations, a common characteristic in the early-to-mid-stage biotech sector where companies often rely on equity financing to fund their pipelines.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from the SEPA share issuance. The Series A Preferred Stock's preferential rights and high voting power could diminish the influence and economic interest of common stockholders. The history of reverse stock splits indicates a negative impact on share value over time.
• Creditors: The capital raise through SEPA could improve the company's liquidity and financial stability, potentially reducing credit risk.
• Management/Board: The SEPA provides a flexible funding mechanism, supporting management's ability to execute strategic plans. The corporate governance provisions reinforce board control and stability.

Next Steps

• Hold a Special Meeting of Stockholders on February 18, 2026, to vote on the proposals.
• If Proposal 2 (SEPA Share Issuance) is approved, the company may proceed with issuing shares to Yorkville under the SEPA to fund operations.
• File a Current Report on Form 8-K within four business days after the Special Meeting to publish final voting results.
• Continue to operate and pursue business development opportunities, potentially utilizing the SEPA for funding.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, evidenced by the need for a potentially highly dilutive Standby Equity Purchase Agreement (SEPA) and a history of multiple reverse stock splits (four in five years). While the SEPA provides a necessary capital lifeline, it comes at the cost of significant shareholder dilution. The existence of Series A Preferred Stock with superior voting and liquidation rights further disadvantages common stockholders. The high thresholds for corporate governance changes also limit shareholder influence. These factors, combined with the lack of positive operational or clinical updates in this filing, suggest a high-risk investment with a strong likelihood of further value erosion for common shareholders. A seasoned investor would likely view this as a signal to exit or avoid the stock due to ongoing capital needs and structural disadvantages for common equity.

Keywords

Aptevo Therapeutics, APVO, SEC Filing, Proxy Statement, Special Meeting, Equity Offering, Standby Equity Purchase Agreement, SEPA, Stock Dilution, Corporate Governance, Preferred Stock, Reverse Stock Split, Nasdaq Listing Rules, Capital Raise, Yorkville